0GHZ Stock Overview
A pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Xspray Pharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 77.70 |
| 52 Week High | SEK 77.70 |
| 52 Week Low | SEK 33.60 |
| Beta | 0.92 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | 102.36% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 0.40% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0GHZ | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 4.1% | 1.7% |
| 1Y | 102.4% | -14.2% | 9.0% |
Return vs Industry: 0GHZ exceeded the UK Biotechs industry which returned -16.9% over the past year.
Return vs Market: 0GHZ exceeded the UK Market which returned 9.3% over the past year.
Price Volatility
| 0GHZ volatility | |
|---|---|
| 0GHZ Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.4% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0GHZ's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine 0GHZ's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 26 | Per Andersson | www.xspraypharma.com |
Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company’s product candidates include Dasynoc, a trailblazer, under approval phase for the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib, under pivotal studies for the treatment of chronic myeloid leukemia; XS008, based on axitinib, under development for treatment of kidney cancer; and XS00Y under development phase. It has partnership agreements with EVERSANA for the commercialization of Dasynoc, as well as with NerPharMa for commercial production of Dasynoc.
Xspray Pharma AB (publ) Fundamentals Summary
| 0GHZ fundamental statistics | |
|---|---|
| Market cap | SEK 1.63b |
| Earnings (TTM) | -SEK 214.76m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-7.6x
P/E RatioIs 0GHZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0GHZ income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 214.76m |
| Earnings | -SEK 214.76m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 06, 2024
| Earnings per share (EPS) | -6.36 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 0GHZ perform over the long term?
See historical performance and comparison